Results 191 to 200 of about 713,346 (360)

Biphasic actions of the adenosine A2a receptor antagonist istradefylline in mice with obstructive uropathy. [PDF]

Sci Rep
Yeung ESH, Tran DT, Batchu SN, Advani SL, Liu Y, Kaur H, Yuen DA, Aslam R, Luk CT, Advani A.   +9 more
europepmc   +1 more source

The α₁‐Adrenergic Receptor Antagonist, Doxazosin, Reduces Alcohol Drinking in Alcohol‐Preferring (P) Rats [PDF]

, 2012
Meghan L. O’Neil, Lauren E. Beckwith, Carrie Kincaid, Dennis D. Rasmussen   +3 more
openalex   +1 more source

Therapeutic strategies for MMAE‐resistant bladder cancer through DPP4 inhibition

Molecular Oncology, EarlyView.
We established monomethyl auristatin E (MMAE)‐resistant bladder cancer (BC) cell lines by exposure to progressively increasing concentrations of MMAE in vitro. RNA sequencing showed DPP4 expression was increased in MMAE‐resistant BC cells. Both si‐DPP4 and the DPP4 inhibitor sitagliptin suppressed the viability of MMAE‐resistant BC cells.
Gang Li, Shuichi Tatarano, Hirofumi Yoshino, Saeki Saito, Mitsuhiko Tominaga, Junya Arima, Ikumi Fukuda, Takashi Sakaguchi, Ryosuke Matsushita, Yasutoshi Yamada, Hideki Enokida   +10 more
wiley   +1 more source

Finerenone as a Nonsteroidal Mineralocorticoid Receptor Antagonist for Lupus Nephritis. [PDF]

Kidney Int Rep
Sun M, Xiao F, Chen X, Wang L, Dai H.
europepmc   +1 more source

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

Molecular Oncology, EarlyView.
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala, Sini Ahonen, Sara Peltola, Aura Tuohisto‐Kokko, Olaya Esparta, Peppi Suominen, Anne Jokilammi, Iman Farahani, Deepankar Chakroborty, Nikol Dibus, Steffen Boettcher, Tomi T. Airenne, Mark S. Johnson, Lisa D. Eli, Klaus Elenius, Kari J. Kurppa   +15 more
wiley   +1 more source

Proton Pump Inhibitor-Induced Fundic Gland Polyps With Massive Bleeding Regressed on Alternative Histamine 2 Receptor Antagonist Therapy. [PDF]

DEN Open
Ikeda R, Kaneko H, Sato H, Matsuoka Y, Hamaguchi T, Ikeda A, Goda Y, Sue S, Irie K, Maeda S.   +9 more
europepmc   +1 more source

Discovery of novel, potent, and orally active spiro-urea human glucagon receptor antagonists

, 2005
Dong‐Ming Shen, Fengqi Zhang, Edward J. Brady, Mari R. Candelore, Qing Dallas-Yang, Victor Ding, Jasminka Dragovic, William P. Feeney, Guoquiang Jiang, Peggy E. McCann, Steve Mock, Sajjad A. Qureshi, Richard Saperstein, Xiaolan Shen, Constantin Tamvakopoulos, Xinchun Tong, Laurie Tota, Michael Wright, Xiaodong Yang, Song Guo Zheng, Kevin T. Chapman, Bei B. Zhang, James R. Tata, Emma R. Parmee   +23 more
openalex   +1 more source

Cross-interactions of Two p38 Mitogen-activated Protein (MAP) Kinase Inhibitors and Two Cholecystokinin (CCK) Receptor Antagonists with the CCK1 Receptor and P38 MAP Kinase [PDF]

, 2005
Caroline Morel, Géraldine Ibarz, Catherine Oiry, Eric Carnazzi, Gilbert Bergé, Didier Gagne, Jean‐Claude Galleyrand, Jean Martínez   +7 more
openalex   +1 more source

Peroxidasin enables melanoma immune escape by inhibiting natural killer cell cytotoxicity

Molecular Oncology, EarlyView.
Peroxidasin (PXDN) is secreted by melanoma cells and binds the NK cell receptor NKG2D, thereby suppressing NK cell activation and cytotoxicity. PXDN depletion restores NKG2D signaling and enables effective NK cell–mediated melanoma killing. These findings identify PXDN as a previously unrecognized immune evasion factor and a potential target to improve
Hsu‐Min Sung, David Bickel, Lena C. M. Krause, Daria Ezeriņa, Christian Ickes, Julian Wojtachnia, Christine S. Gibhardt, Magdalena Shumanska, Khadija Wahni, Andrea Paluschkiwitz, Julia Malo Pueyo, Ekaterina Baranova, Wim Vranken, Hedwig Stanisz, Ioana Stejerean‐Todoran, Michael P. Schön, Joris Messens, Ivan Bogeski   +17 more
wiley   +1 more source

IL-1 receptor antagonist as a diagnostic biomarker for bacterial infections in acute decompensation of cirrhosis. [PDF]

Sci Rep
Konstantis G, Schütte A, Jung B, Passenberg M, Jacquet L, Guntlisbergen C, Nuruzade N, Hoyer DP, Best J, Willuweit K, Schmidt HH, Guckenbiehl S, Rashidi-Alavijeh J.   +12 more
europepmc   +1 more source